NCT06791941 Study of the Contribution of Mutant p53/YAP Proteins to Therapy Resistance in Recurrent Head and Neck Cancer
| NCT ID | NCT06791941 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Regina Elena Cancer Institute |
| Condition | Head and Neck Tumors |
| Study Type | OBSERVATIONAL |
| Enrollment | 18 participants |
| Start Date | 2024-03-07 |
| Primary Completion | 2029-03-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 18 participants in total. It began in 2024-03-07 with a primary completion date of 2029-03-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multicenter, non-interventional, retrospective/prospective study of a biological nature, on patients affected by head and neck tumors, for which the collection and use of tissue samples is planned for the study of the mutational profile, the transcriptional profile and the proteomic profile.
Eligibility Criteria
Inclusion Criteria: * Age over 18 * Patients with squamous cell tumors of the oral cavity, pharynx or larynx * Surgical patients with primary HNSCC tumors, who have not had previous tumors in other sites or adjuvant treatments prior to surgery. * Availability of adequate material (tissue) for the planned analyses * Availability of follow-up data for at least one year (retrospective part) * Written informed consent (prospective part and/or, for the retrospective part, traceable patients and/or patients in follow-up and/or if necessary for the legal nature/institutional purposes of the participating centers). Exclusion Criteria: * Presence of distant metastases at the time of diagnosis * Previous head and neck cancer * Second cancer undergoing treatment or follow-up for less than 5 years
Contact & Investigator
Giovanni Blandino, Doctor
PRINCIPAL INVESTIGATOR
IRCCS National Cancer Institute
Frequently Asked Questions
Who can join the NCT06791941 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Head and Neck Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06791941 currently recruiting?
Yes, NCT06791941 is actively recruiting participants. Contact the research team at giovanni.balndino@ifo.it for enrollment information.
Where is the NCT06791941 trial being conducted?
This trial is being conducted at Roma, Italy.
Who is sponsoring the NCT06791941 clinical trial?
NCT06791941 is sponsored by Regina Elena Cancer Institute. The principal investigator is Giovanni Blandino, Doctor at IRCCS National Cancer Institute. The trial plans to enroll 18 participants.